Ovarian cancer ascites protects from TRAIL-induced cell death through αvΒ5 integrin-mediated focal adhesion kinase and Akt activation

Oncogene

Volumn 29, Issue 24, 2010, Pages 3519-3531

  Lane, D ^a   Goncharenko Khaider, N ^a   Rancourt, C ^a   Piche A ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

Ascites; Death receptors; Integrins; Ovarian carcinoma; PI3K Akt pathway; TRAIL

Indexed keywords

ALPHAVBETA5 INTEGRIN; BETA1 INTEGRIN; BETA3 INTEGRIN; CASPASE 3; CASPASE 8; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR; FLICE INHIBITORY PROTEIN; FOCAL ADHESION KINASE; PROTEIN KINASE B; RECEPTOR ANTIBODY; SOMATOMEDIN C RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULOTROPIN RECEPTOR;

ARTICLE; ASCITES; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; HEAT; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DEPLETION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION;

ASCITES; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; ENZYME ACTIVATION; FEMALE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GENE KNOCKDOWN TECHNIQUES; HOT TEMPERATURE; HUMANS; MOLECULAR WEIGHT; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VITRONECTIN; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 77953811126     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.107     Document Type: Article

References (43)

1. Abendstein B, Stadimann S, Knabbe C, Buck M, Muller-Holzner E, Zeimet AG et al. (2000). Regulation of transforming growth factor-beta secretion by human peritoneal mesothelial and ovarian carcinoma cells. Cytokine 12: 1115-1119.
2. Alper O, Bergmann-Leitner ES, Bennett TA, Hacker NF, Stromberg K, Stetler-Stevenson WG. (2001). Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst 93: 1375-1384.
3. Carreiras F, Rigot V, Cruet S, Andre F, Gauduchon P, Marvaldi J. (1999). Migration properties of the human ovarian adenocarcinoma cell line IGROV1: importance of alpha(v)beta3 integrins and vitronectin. Int J Cancer 80: 285-294.
4. Contos JJ, Ishii I, Chun J. (2000). Lysophosphatidic acid receptors. Mol Pharmacol 58: 1188-1196.
5. Cruet-Hennequart S, Maubant S, Luis J, Gauduchon P, Staedel C, Dedhar S. (2003). Alpha(v) integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells. Oncogene 22: 1688-1702.
6. Damiano JS. (2002). Integrins as novel drug targets for overcoming innate drug resistance. Curr Cancer Drug Targets 2: 37-43.
7. Dan HC, Jiang K, Coppola D, Hamilton A, Nicosia SV, Sebti SM et al. (2004). Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis. Oncogene 23: 706-715.
8. Davidson B, Espina V, Steinberg SM, Florenes VA, Liotta LA, Kristensen GB et al. (2006). Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling. Clin Cancer Res 12: 791-799.
9. Fornaro M, Plescia J, Chheang S, Tallini G, Zhu Y-M, King M et al. (2003). Fibronectin protects prostate cancer cells from tumor necrosis factor-alpha-induced apoptosis via the AKT/survivin pathway. J Biol Chem 278: 50402-50411.
10. Fraser M, Leung BM, Yan X, Dan HC, Cheng JQ, Tsang BK. (2003). Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res 63: 7081-7088.
11. Frisch SM, Ruoslahti E. (1997). Integrins and anoikis. Curr Opin Cell Biol 9: 701-706.
12. Goetzl EJ, Dolezalova H, Kong Y, HU Y-L, Jaffe RB, Kalli KR et al. (1999). Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lyso-phosphatidic acid in ovarian cancer. Cancer Res 59: 5370-5375.
13. Gillan L, Matei D, Fishman DA, Gerbin CS, Karlan BY, Chang DD. (2002). Periostin secreted by epithelial ovarian carcinoma is a ligand for avb3 and avb5 integrins and promotes cell motility. Cancer Res 62: 5358-5364.
14. Graves LE, Ariztia EV, Navari JR, Matzel HJ, Stack S, Fishman DA. (2004). Proinvasive properties of ovarian cancer ascites-derived membrane vesicles. Cancer Res 64: 7045-7049.
15. Hynes RO. (1992). Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69: 11-25.
16. Kandasamy K, Srivastava RK. (2002). Role of the phosphatidylino-sitol 3-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. Cancer Res 62: 4929-4937.
17. Kang YC, Kim KM, Lee KS, Namkoong S, Lee SJ, Han JA et al. (2004). Serum bioactive lysophospholipids prevent TRAIL-induced apoptosis via PI3K/Akt-dependent cFLIP expression and Bad phosphorylation. Cell Death Differ 11: 1287-1298.
18. Kobayashi-Sakamoto M, Isogai E, Hirose K, Chiba I. (2008). Role of av integrin in osteoprotegerin-induced endothelial cell migration and proliferation. Microvasc Res 76: 139-144.
19. Kohler M, Janz I, Winter HO, Wagner E, Bauknecht T. (1989). The expression of EGF receptors, EGF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance. Anticancer Res 9: 1537-1547.
20. Kohler M, Bauknecht T, Grimm M, Birmelin G, Kommoss F, Wagner E. (1992). Epidermal growth factor receptor and transforming growth factor alpha expression in human ovarian carcinomas. Eur J Cancer 28: 1432-1437.
21. Lane D, Robert V, Grondin R, Rancourt C, Piche A. (2007). Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian cancer cells. Int J Cancer 121: 1227-1237.
22. Lane D, Cartier A, Rancourt R, Piche A. (2008). Cell detachment modulates TRAIL resistance in ovarian cancer cells by down-regulating the phosphatidylinositol 3-kinase/Akt pathway. Int J Gynecol Oncol 18: 670-676.
23. Matei D, Emerson RE, Lai Y-C, Baldridge LA, Rao J, Yiannoutsos C et al. (2006). Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer. Oncogene 25: 2060-2069.
24. Matter ML, Ruoslahti E. (2001). A signaling pathway from the alpha5beta1 and alpha(v)beta3 integrins that elevates bcl-2 transcription. J Biol Chem 276: 27757-27763.
25. Mills GB, May C, McGill M, Rofiman CM, Mellors A. (1988). A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. Cancer Res 48: 1066-1071.
26. Mills GB, Moolenaar WH. (2003). The emerging role of lysopho-sphatidic acid in cancer. Nat Rev Cancer 3: 582-591.
27. Miyamoto S, Hirata M, Yamazaki A, Kageyama T, Hasuwa H, Mizushima H et al. (2004). Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res 64: 5720-5727.
28. Noguchi K, Ishii S, Shimizu T. (2003). Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem 278: 25600-25606.
29. Puiffe M-L, Le Page C, Filali-Mouhim A, Zietarska M, Ouellet V, Tonin PN et al. (2007). Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia 9: 820-829.
30. Puls LE, Duniho T, Hunter JE, Kryscho R, Blackhurst D, Gallion H. (1996). The prognostic implication of ascites in advanced-stage ovarian cancer. Gynecol Oncol 61: 109-112.
31. Ren J, Xiao Y-J, Singh LS, Zhao X, Zhao Z, Feng L et al. (2006). Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. Cancer Res 66: 3006-3014.
32. Saltzman AK, Hartenbach EM, Carter JR, Contreras DN, Twiggs LB, Carson LF et al. (1999). Transforming growth factor-alpha levels in the serum and ascites of patients with advanced epithelial ovarian cancer. Gynecol Obstet Invest 47: 200-204.
33. Shen-Gunther J, Mannel RS. (2002). Ascites as a predictor of ovarian malignancy. Gynecol Oncol 87: 77-83.
34. Sivaprasad U, Shankar E, Basu A. (2007). Downregulation of Bid is associated with PKCepsilon-mediated TRAIL resistance. Cell Death Differ 14: 851-860.
35. Stoica A, Saceda M, Fakhro A, Joyner M, Martin MB. (2000). Role of insulin-like growth factor-I in regulating estrogen receptor-alpha gene expression. J Cell Biochem 76: 605-614.
36. Stupack DG, Cheresh DA. (2002). Get a ligand, get a life: integrins, signaling and cell survival. J Cell Science 115: 3729-3738.
37. Uhm JH, Dooley NP, Kyritsis AP, Rao JS. (1999). Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. Clin Cancer Res 5: 1587-1594.
38. Westermann AM, Havik E, Postma FR, Beijenen JH, Dalesio O, Moolenaar WH et al. (1998). Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol 9: 437-442.
39. Yamada T, Sato K, Komachi M, Malchinkhuu E, Tobo M, Kimura T et al. (2004). Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. J Biol Chem 279: 6595-6605.
40. Yang X, Fraser M, Moll UM, Basak A, Tsang BK. (2006). Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res 66: 3126-3136.
41. Yarden Y, Sliwkowski MX. (2001). Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137.
42. Ye X, Ishii I, Kingsbury MA, Chun J. (2002). Lysophosphatidic acid as a novel cell survival/apoptotic factor. Biochim Biophys Acta 1585: 108-113.
43. Zhang Z, Vuori K, Reed JC, Ruslahti E. (1995). The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. Proc Natl Acad Sci USA 92: 6161-6165.